Labs / Assays & in vitro testing
Receptor
London, United Kingdom · receptor.ai
Receptor.AI develops AI-driven drug discovery platforms for therapeutic molecule design. It works on small molecules, peptides, and biologics/proximity modalities for drug discovery projects and co-development programs, with headquarters in London and operations linked to Central Europe and the US.
Their website has a general contact form; we send your quote request through it.
What they offer
Small Molecules Platform
AI drug discovery workflows for target classes such as kinases, GPCRs, ion channels, and enzymes, including pocket identification, SAR analysis, virtual screening, selectivity optimization, and ADMET prediction.
Peptide Platform
De novo design of peptides and binders, including orally bioavailable peptides, with optimization of activity, permeability, and oral availability.
Biologics & Proximity Platform
Design of proximity inducers and antibody-enabled therapeutics, including degraders, molecular glues, PPI disruptors, bispecifics, and immune cell engagers.
End-to-end peptide discovery platform
Therapeutic peptide discovery from hit identification to drug candidates, with orchestration across the peptide DMTA cycle and software access.
Co-development programs
Co-development projects progressing from hit discovery to preclinical stage for selected therapeutic targets.
Platform access
SaaS access to the drug discovery platform for target-to-lead workflows.
Drug design consultancy
Consultancy on drug discovery and platform-based molecular design projects.
What they work on
- Modalities
- Small molecule, Antibody, Bispecific, ADC, Peptide, Recombinant protein
- Assays and studies
- SAR analysis, virtual screening, ADMET prediction, protein-ligand preparation, PPI structure prediction, ternary complex prediction
- Therapeutic areas
- nephrology, oncology, inflammation, cardiology
- What to send
- target sequence or available 3D structure · request details via contact form
- Sites
- Kyiv, Ukraine · London, United Kingdom · Central Europe
- Team
- 15 experts
- Serves
- Japan
- Address
- 2024 Expanded Scientific Leadership Dr. Rajiah Aldrin Denny joined as Chief Scientific Advisor. Dr. Tomi K
- Founded
- 2021
Public records
- Ownership
- Receptor Holding ApS · DK GLEIF
Similar labs. Aurigene Pharmaceutical Services, Sparx BIO, Sai Life, Evotec
Found in a contract services directory. Listing built from receptor.ai. Work here? Claim this listing.